The Food and Drug Administration has approved a novel type of cholesterol-lowering drug jointly developed by Alnylam Pharmaceuticals and Novartis. The treatment, called Leqvio, uses RNA to help keep levels of low-density lipoprotein (LDL) cholesterol in the blood low, which is important for people with certain…
Read more…
Source : FDA Approves a New RNA-Based Treatment to Lower Cholesterol
